527 reports of this reaction
2.8% of all SIPONIMOD reports
#4 most reported adverse reaction
GAIT DISTURBANCE is the #4 most commonly reported adverse reaction for SIPONIMOD, manufactured by Novartis Pharmaceuticals Corporation. There are 527 FDA adverse event reports linking SIPONIMOD to GAIT DISTURBANCE. This represents approximately 2.8% of all 19,111 adverse event reports for this drug.
Patients taking SIPONIMOD who experience gait disturbance should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GAIT DISTURBANCE is a less commonly reported adverse event for SIPONIMOD, but still significant enough to appear in the safety profile.
In addition to gait disturbance, the following adverse reactions have been reported for SIPONIMOD:
The following drugs have also been linked to gait disturbance in FDA adverse event reports:
GAIT DISTURBANCE has been reported as an adverse event in 527 FDA reports for SIPONIMOD. This does not prove causation, but indicates an association observed in post-market surveillance data.
GAIT DISTURBANCE accounts for approximately 2.8% of all adverse event reports for SIPONIMOD, making it a notable side effect.
If you experience gait disturbance while taking SIPONIMOD, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.